本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Expanded shareholder group, led by global investors including Neuberger Berman Private Markets, CPP Investments, CF Alba and Dubai Holding, brings deep expertise and long-term capital to support Nord Anglia's continued expansion and innovation in premium education USD 14.5 billion transaction reflects Nord Anglia's leadership in delivering world-class education and its position as a premier global institution The depth and diversity of global financial asset managers and institutions in Nord Anglia's expanded shareholder base enhance its long-term resilience, introduce fresh strategic capital and create new pathways for innovation and growth LONDON, March 20, 2025 /PRNewswire/ -- EQT, as part of a global consortium of premier institutional investors including Neuberger Berman Private Markets, Canada Pension Plan Investment Board ("CPP Investments"), Corporación Financiera Alba, S.A. ("CF Alba") and Dubai Holding Investments ("Dubai Holding") (collectively the "Consortium"), today announced the successful completion of the Consortium's acquisition of Nord Anglia Education ("Nord Anglia" or the "Company"), valuing the business at USD 14.5 billion.This transaction marks a significant milestone in Nord Anglia's evolution as a global leader in private international education. Operating over 80 schools in 33 countries, Nord Anglia educates more than 90,000 students from ages 2 to 18. Its students consistently achieve excellent academic results, with Year 12 graduates frequently accepted into the world's top 100 universities. Central to Nord Anglia's educational philosophy is its personalized learning approach, where classroom teaching is tailored to each student's unique learning style.Alongside EQT, Neuberger Berman Private Markets, CPP Investments, CF Alba and Dubai Holding, the completion of Nord Anglia's acquisition also introduces a distinguished group of global financial asset managers or institutions which significantly broadens and strengthens the Company's ownership structure. This group includes sovereign wealth funds, insurers, and family offices across Asia, the Middle East, Europe, and North America, which not only enhances Nord Anglia's long-term stability as a private company but also brings new strategic perspectives, resources, and capital to drive its continued growth. The strong momentum and commitment from these investors reflect the exceptional quality of the organization and confidence in its long-term trajectory.EQT has been a dedicated partner to Nord Anglia since 2008 and further strengthened its commitment in 2017, when CPP Investments joined as an investor. Over this period, EQT has played a central role in strategic M&A, helping Nord Anglia successfully execute more than 21 acquisitions since 2017 that have significantly expanded its footprint and earnings. Additionally, EQT has worked closely with Nord Anglia to invest in digital initiatives, enhancing both the student learning experience and operational efficiencies. Under EQT's ownership, Nord Anglia has also established an innovative collaboration model with world-renowned institutions, further elevating its reputation for academic excellence. Its partners include UNICEF, Juilliard, MIT, IMG Academy, King's College London, and Project Zero, a research center at the Harvard Graduate School of Education.Neuberger Berman, CF Alba, Dubai Holding and other leading global investors now join EQT and CPP Investments to further strengthen Nord Anglia's position as a sophisticated, globally integrated premium education group. With a commitment to supporting both organic growth and strategic acquisitions, the Consortium ensures Nord Anglia remains well-positioned for continued innovation, expansion, and leadership in the evolving global education landscape.Jean Eric Salata, Chairperson of EQT Asia and Head of Private Capital Asia, said, "EQT is proud to be a long-term partner to Nord Anglia and to continue supporting its evolution as a world-leading premium education platform. This transaction not only delivers a strong outcome and a successful exit for BPEA Private Equity Fund VI but also marks a defining moment for EQT, as we align with a distinguished group of global investors who share a deep commitment to Nord Anglia's mission. The strength and diversity of this expanded shareholder base will reinforce the company's long-term stability, provide additional strategic capital, and unlock new opportunities for innovation. We look forward to this next chapter and to seeing Nord Anglia continue to set new benchmarks in academic excellence and global impact."Jack Hennessy, Partner at EQT Private Equity, said, "Nord Anglia is an outstanding institution that has set new standards for excellence in global private education. For more than 16 years, we've worked closely with the company's exceptional management team to expand its reach and elevate its academic offering. With the completion of this transaction, we are excited to continue this journey with Neuberger Berman, CPP Investments, CF Alba, Dubai Holding and a world-class group of long-term institutional investors, ensuring Nord Anglia is well-positioned for its next stage of growth."Andrew Fitzmaurice, Chief Executive Officer of Nord Anglia Education, added, "We are delighted to partner with some of the world's most respected investors, who share our commitment to educational excellence. EQT has been an exceptional partner over the years, helping to strengthen our academic programs, invest in research and innovation, and expand our family of schools globally. With the support of our investor group, we are excited about the future and the opportunities this will create to further improve students' outcomes."EQT is investing in Nord Anglia through its BPEA Private Equity Fund VIII. ContactEQT Press Office, press@eqtpartners.com This information was brought to you by Cision http://news.cision.com https://news.cision.com/eqt/r/eqt-consortium-completes-acquisition-of-nord-anglia-education,c4121535 The following files are available for download: https://mb.cision.com/Main/87/4121535/3331621.pdf 250320 EQT Consortium Completes Acquisition of Nord Anglia https://news.cision.com/eqt/i/avenues-new-york---nae,c3388678 Avenues New York - NAE
NORWOOD, Mass., March 19, 2025 /PRNewswire/ -- Patricia Industries' subsidiary Advanced Instruments, a manufacturer of analytical instruments for the biopharmaceutical and clinical markets, today announced the execution of a definitive agreement to acquire Nova Biomedical, a manufacturer of innovative analytical instruments and consumables that are vital in guiding the treatment of patients and the development of biotechnology therapeutics. Following the closing of the transaction, Advanced Instruments and Nova Biomedical will merge, creating a global life science tools platform that will operate under the Nova Biomedical name, with a diversified portfolio of analytical instruments, reagents and services. Byron Selman, President & CEO of Advanced Instruments, will lead the combined business, while Nova Biomedical founding shareholders Frank Manganaro, CEO and Dr. Chung-Chang Young, EVP of R&D, will stay with the company in a consulting capacity. For the full year 2024, the combined business generated sales of $621M. Over the past 10 years, pro forma organic sales growth has averaged approximately 8 percent. "Combining these two great companies aligns with our core strategy to develop and commercialize best-in-class technologies that deliver significant customer value across the biopharma and clinical markets," commented Mr. Selman. "The combination of our technologies, R&D strength, global sales network, dedicated teams and commitment to innovation will advance our collective ability to support customer workflows within various stages of drug development and bioprocessing and expand our footprint within the hospital and other healthcare settings, guiding patient care with our diversified product portfolio and supporting our growing customer base." "We are excited to unite with the Advanced Instruments team," said Mr. Manganaro. "Our companies share similar values and objectives including a vision for sustained innovation, a strong commitment to the end markets we respectively serve and above all a strong connection to improving patient care globally. Bringing together our strong teams, focus on innovation and dedication to the customer will strengthen our combined companies and support a bright future for Nova Biomedical." "Growing our platform companies within Patricia Industries is a key priority for us, and we are excited to accelerate Advanced Instruments' growth journey with the acquisition of Nova Biomedical, whose talented team we welcome to the Patricia Industries family," said Yuriy Prilutskiy, Co-Head of Patricia Industries, a part of Investor AB and owner of Advanced Instruments. "The combined business will be well-positioned to bring innovative technologies to customers across the clinical and bioprocessing markets, enable patients globally to receive better healthcare, and deliver long-term profitable growth – all of which align with our purpose of creating value for people and society by building strong and sustainable businesses." Closing is subject to regulatory approval and is expected during the third quarter of 2025. Advanced Instruments was represented by UBS Investment Bank (financial advisor), Simpson Thacher & Bartlett LLP (legal advisor) and Cooley LLP (legal advisor). Nova Biomedical was represented by Jefferies (financial advisor) and David Polk & Wardwell LLP (legal advisor). For Further Information:Advanced InstrumentsContact: Lisa Fahey603-438-9080 About Advanced Instruments Advanced Instruments is a global provider of scientific and analytical instruments for the biotechnology, clinical, and food and beverage industries. For more than 70 years, the company's innovations have helped organizations improve quality of results, achieve reliable outcomes, and increase workplace productivity. Advanced Instruments has a diverse portfolio of products, including freezing point osmometers, technologies for cell line development, liquid handling verification instrumentation, cerebrospinal fluid cell counters, anaerobic jar systems, and testing standards and controls. Advanced Instruments is based in Norwood, Massachusetts and is majority owned by Patricia Industries. For more information, visit www.aicompanies.com. About Nova Biomedical Nova Biomedical is a global provider of analytical instruments and consumables for the biopharmaceutical and clinical markets. The company's innovative products are used in over 100 countries by leading biopharmaceutical companies and hospitals. Nova's clinical products provide point-of-care analysis and monitoring of critical analytes including blood gases and glucose used to diagnose and monitor patients in hospital settings. Nova's biopharmaceutical products provide mission-critical analytics for research laboratories and drug manufacturing facilities, accelerating and improving the drug development process and product quality. Nova is headquartered in Waltham, Massachusetts and has approximately 1,600 employees. www.novabiomedical.com About Patricia Industries Patricia Industries, a part of Investor AB, makes control investments in best-in-class companies with strong market positions, brands and corporate cultures within industries positioned for secular growth. Our ambition is to be the sole owner of our companies, together with strong management teams and boards. We invest with an indefinite holding period and focus on building durable value and capturing organic and non-organic growth opportunities. For more information, visit www.patriciaindustries.com. About Investor AB Investor, founded by the Wallenberg family in 1916, is an engaged owner of high-quality, global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. For more information, visit www.investorab.com.
KUALA LUMPUR, Malaysia, March 19, 2025 /PRNewswire/ -- TECO Electric & Machinery Co. held an acquisition signing ceremony today (19th) in Kuala Lumpur, Malaysia, with local MEP engineering company NCL Energy Sdn Bhd (hereinafter referred to as NCL). TECO will acquire an 80% stake in NCL, becoming its largest shareholder and jointly expanding into Malaysia's MEP engineering market for data centers and renewable energy. TECO Chairman Morris Li stated that Malaysia has introduced a series of power infrastructure and renewable energy policies. With its low electricity costs, vast land availability, and strategic location near Singapore, Malaysia has attracted significant investment in data center construction, making it the country with the highest number of new data centers in Southeast Asia. This acquisition aligns with TECO's strategy of focusing on the Southeast Asian market and demonstrates its long-term commitment to the Malaysian market. On March 14, TECO's board of directors approved the acquisition and investment of NCL Energy Sdn Bhd and its renewable energy subsidiary, NCL Green Energy Sdn Bhd, for a total price not exceeding MYR 70 million. The transaction is expected to be completed in Q2 2025. TECO's Intelligence Energy Business Group has extensive experience in building data centers for international cloud computing giants in Taiwan and Singapore. Chairman Li highlighted that NCL has been a long-term strategic partner of Malaysia's electricity company, Tenaga Nasional Berhad (TNB). With NCL's experienced team and past achievements, TECO will be able to quickly obtain the necessary MEP engineering licenses and workforce for the Malaysian market. Furthermore, this acquisition will allow TECO to seamlessly connect with major Malaysian EPC contractors such as Gamuda and Sunway, enabling it to provide comprehensive MEP engineering services for international cloud computing clients in Malaysia. NCL founder Dato' Ng Keng Hiong expressed his honor in joining the TECO Group. NCL has been engaged in MEP and solar engineering in Malaysia for nearly 20 years. Recently, it successfully collaborated with TECO on two hyperscale data center projects, establishing a strong working relationship. This investment signifies TECO's recognition of NCL's management team. With greater capital and resources, NCL aims to expand its team and compete for more large-scale data center, solar power plant, and MEP engineering projects. Malaysia has attracted strategic investments from global tech giants such as Google, Microsoft, Amazon Web Services, and Oracle. Over the next five years, the country is expected to receive more than $20 billion in foreign investment for data center construction, solidifying its position as Southeast Asia's data center hub. Chairman Li emphasized that entering Malaysia's data center MEP engineering market is just the first step. TECO plans to expand into solar power plant, battery energy storage system (BESS), EV charging and MEP equipment sales to seize market opportunities. This aligns with TECO's strategy of increasing overseas revenue to more than 50% within the next two to three years by targeting Southeast Asia's high-growth potential markets. Through this initiative, TECO aims to fulfill its vision in realizing electrification, intelligence, and green energy.
BOSTON, March 17, 2025 /PRNewswire/ -- PartnerOne, one of the fastest growing enterprise software conglomerates in the world, has announced that it has successfully acquired NetWitness from RSA. NetWitness NetWitness is a leader in cybersecurity that delivers highly scalable threat detection and response solutions. Its solutions empower security analysts with better and more efficient tools to keep security operations well ahead of business-impacting threats. NetWitness achieves this with best-in-class threat detection, investigation & response platforms which have the ability to automate and orchestrate the incident response lifecycle. PartnerOne's acquisition of NetWitness is great news for its customers and partners. With its existing expertise across government and commercial entities in the cybersecurity space, PartnerOne will help NetWitness improve its technology and increase its capabilities. PartnerOne acquires, invests and grows its companies, and NetWitness now has a forever-home and the financial backing to solidify its position as a market leader. "NetWitness is very excited to be a part of PartnerOne's successful portfolio of enterprise software companies. We know that PartnerOne's expertise and financial strength will help us to innovate, invest in our technology, and deliver industry-leading service to our large enterprise customer base." Said Julie Burgoyne, Executive Vice President. NetWitness will operate as an independent company with the full strength and support of PartnerOne behind it. About RSA: RSA is a leader in identity security solutions for the world's most security-sensitive organizations delivering automated identity intelligence, authentication, access, governance, and lifecycle capabilities to defend against the highest-impact cybersecurity risks. About PartnerOne: PartnerOne is one of the fastest growing enterprise software groups in the world, with a proven track record of acquiring and growing enterprise software companies. Over 1500 enterprise and government organizations rely on PartnerOne software, including 80% of the largest companies in the world. About NetWitness: Founded in 1997, NetWitness is a threat detection & cyber security monitoring company. The NetWitness platform combines visibility, analytics, and automation into a single solution allowing customers to prioritize, respond, reconstruct, survey, investigate and confirm information about the threats in their environment and take the appropriate response—quickly and precisely. For more information, please contact legal@partnerone.com
Healthcare Holding Schweiz AG, a leading service provider and distributor of medical devices in Switzerland, is expanding its portfolio with the acquisition of Effectum CH-Rep AG. Healthcare Holding Schweiz is managed by Winterberg Advisory GmbH. BAAR, Switzerland, March 17, 2025 /PRNewswire/ -- Healthcare Holding Schweiz AG has successfully completed the acquisition of Effectum CH-Rep AG. This transaction marks a carve-out of all services provided as Swiss Authorized Representative (CH-REP) from Effectum Medical AG. Under the Medical Devices Ordinance (MedDO SR 812.213) effective since May 26, 2021, manufacturers of medical devices without a registered office in Switzerland must appoint a CH-REP to distribute their products within the country. Through this acquisition, Healthcare Holding Schweiz AG strengthens its position as a comprehensive partner for medical technology manufacturers worldwide. With its group of companies, it can now provide integrated services that encompass not only import and distribution but also full compliance with regulatory requirements. Transaction successfully closed, from left to right: Florian Angstmann, MME Legal, Fabio Fagagnini, CEO of Healthcare Holding Schweiz AG, Fabian Kroeher, President of the Board of Healthcare Holding Schweiz AG, Carina Kandrian, Founder of Effectum Medical AG, Michael Eggimann, Board Member of Effectum Medical AG, Philipp Pielmeier, CFO of Healthcare Holding Schweiz AG, Gregory Budakov, Managing Director M&A of Healthcare Holding Schweiz AG Fabio Fagagnini, CEO of Healthcare Holding Schweiz, expressed his enthusiasm for the acquisition: "With Effectum CH-Rep, we are expanding our service portfolio to include the role of Swiss Authorized Representative, thereby strengthening our growing group. This allows our sales representatives and managing directors to focus even more on innovative products and exceptional customer service, with the assurance that all regulatory requirements are being professionally met." Kim Züger, Head of Quality Management & Regulatory Affairs and the newly appointed Director of Effectum CH-Rep, emphasized: "Regulatory compliance is our top priority. Through Effectum CH-Rep, we offer this service not only to suppliers of Healthcare Holding Schweiz but also to numerous other manufacturers—a clear testament to our professionalism and high-quality standards." Michael Eggimann, Board Member of Effectum Medical AG and responsible for the sale of Effectum CH-Rep AG, added: "We have valued working with Fabio Fagagnini and his team for many years and are confident that Effectum CH-Rep is in excellent hands. This transition allows us to fully concentrate on the further development and distribution of our Legal Manufacturing offering as well as our innovative plug-and-play quality management system, while continuing to collaborate closely with Effectum CH-Rep for the benefit of our customers." About Effectum CH-Rep AG Effectum CH-Rep AG, based in Olten, facilitates access for foreign manufacturers of medical devices to the Swiss market by acting as the Swiss Authorized Representative (CH-REP). As a CH-REP, Effectum CH-Rep AG takes on responsibilities such as ensuring compliance with Swiss registration requirements, collaborating with Swissmedic on preventive and corrective actions, providing a Person Responsible for Regulatory Compliance (PRRC), guaranteeing access to technical documentation, and reporting incidents and complaints. About Healthcare Holding Schweiz AG Healthcare Holding Schweiz AG is a Buy, Build & Technologize platform and a leading provider of medical technology products and services in Switzerland. The group is based in Baar and pursues an ambitious growth strategy through acquisitions, often in the context of succession arrangements, partnerships, and organic growth. Healthcare Holding Schweiz and its group companies are committed to the highest standards of innovation and customer satisfaction. The group consistently leverages technology to make business processes safer and more efficient. As a market leader, the company sets new standards for the industry and offers employees attractive development opportunities. All of the management team holds shares in Healthcare Holding Schweiz, thus forming a dynamic community of entrepreneurs. About Winterberg Advisory GmbH and Winterberg Group AG Winterberg Group AG, based in Zug, operates as an independent family office for its founders. Winterberg mainly invests in SMEs in the German-speaking region, and selectively considers investments in startups and real estate. Winterberg Advisory GmbH is a general partner and fund manager regulated by the German BaFin. Winterberg Advisory has launched numerous private equity funds and is invested in Healthcare Holding Schweiz AG through its funds Winterberg Investment VIII and Winterberg Investment IX. The two Partners and Executive Directors, Fabian Kröher and Florian Brickenstein, manage Healthcare Holding Schweiz AG via its board of directors. For press inquiries, please contact presse@healthcare-holding.ch For more information about Dental Axess AG, visit www.effectum-chrep.com For more information about Healthcare Holding Schweiz AG, visit www.healthcare-holding.ch For more information about the portfolio companies of Healthcare Holding, visit www.senectovia.ch, www.winthermedical.ch, www.mikrona.ch, www.orthowalker.ch, www.mcm-medsys.ch, www.naropa-reha.ch, www.mvb-medizintechnik.ch, www.dentalaxess.com This press release is issued and distributed by Winterberg Advisory GmbH on behalf of Healthcare Holding Schweiz AG.
WOBURN, Mass., March 14, 2025 /PRNewswire/ -- Azurity Pharmaceuticals ("Azurity") announced today the successful completion of its acquisition of Covis Group S.à r.l. ("Covis") from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity. This strategic acquisition reinforces Azurity's leadership in branded pharmaceuticals, harnessing the complementary strengths of both companies across multiple complex dosage forms and therapeutic areas. By combining expertise and resources, Azurity strengthens its ability to deliver medicines to overlooked patients on a global scale. Strategic Benefits of the Acquisition: Expanded Therapeutic Portfolio – The integration of Covis' product portfolio and pipeline enhances Azurity's offerings across ten complex dosage forms and nine key therapeutic areas, including cardiovascular, respiratory, central nervous system, endocrinology, gastrointestinal, hematology, immunology, anti-infectives, and oncology. Global Footprint – The acquisition strengthens Azurity's global footprint, expanding its commercial presence to over 50 countries and enabling greater patient accessibility to life-changing treatments. Azurity and its subsidiaries will employ more than 800 colleagues across North America, Europe and Asia. Key Biopharma Partner of Choice – The combined company is positioned to be a key partner for global life sciences companies looking to develop and commercialize their products, providing partners access to its deep development capabilities and global commercial infrastructure. Accelerated Innovation – By combining expertise and resources, Azurity is positioned to advance innovative treatments furthering Azurity's mission to serve overlooked patients using a unique and accelerated development process – enabling scale and velocity. Next-Gen Commercial Model – The integrated company portfolio will benefit from Azurity's highly efficient and effective commercial model, combining data, analytics, and AI-driven digital capabilities to drive stakeholder engagement using an optimized omnichannel marketing approach. "We are excited to welcome Covis Pharma to Azurity," said Ronald Scarboro, CEO of Azurity. "The efforts of colleagues at both companies, their devotion to overlooked patients, and our culture of execution have brought us together to build this unique, highly differentiated pharmaceutical company. I look forward to all that we will accomplish as we grow globally and embrace new opportunities, driven by our purpose." "I am delighted that Azurity recognized the accomplishments and potential of Covis, and am thankful for the tireless efforts of Covis colleagues in support of patients that benefit from the company's products," said Rajiv De Silva, Chairman of the Board of Covis. "I am confident that the two companies will be able to untap each other's highly complementary capabilities to accelerate development and commercialization of necessary medicines to underserved patients." "QHP Capital is proud to support Azurity in this acquisition, which aligns with our commitment to investing in life sciences and healthcare innovations," said Jeff Edwards, Partner at QHP Capital, the majority owner of Azurity. "It has been our privilege to support and enable Azurity from a small, limited product, US-only company at the start of our investment in 2018 to the global, large, diversified portfolio, high-growth company it is today. We are committed to further enabling Azurity for the significant growth its team is well positioned to execute." Goldman Sachs served as financial advisor and Eversheds Sutherland and White & Case served as legal advisors to Azurity. Guggenheim Securities served as financial advisor to Covis and Reed Smith and A&O Shearman served as legal advisors to Covis. About Azurity Pharmaceuticals:Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity's global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning ten dosage forms and nine key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. For more information, visit www.azurity.com. About QHP Capital: QHP Capital is an investor in technology and services companies in the life sciences, medical technology, and healthcare sectors. QHP has built an investment platform to provide strategic capital and industry expertise in partnership with strong management teams. The investment team consists of seasoned investment and operational professionals with significant investment experience and deep life science, medical technology, and healthcare expertise. QHP benefits from an extensive network of industry experts that assist in identifying, analyzing, and growing QHP's portfolio companies. For more information, please visit www.qhpcapital.com. Disclosure notice: Azurity and QHP undertake no obligation to update or revise any forward-looking statements contained in this release as a result of new information, future events, or evolving circumstances.
A12 藝術空間
Acquisitions, mergers, takeovers
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
